PO.CL09.04 · 临床研究
融合基因机器学习模型改善肝细胞癌的临床结局预测
Fusion gene machine learning models improve clinical outcome prediction of hepatocellular carcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肝细胞癌是人类最致命的恶性肿瘤之一。评估HCC的临床结局仍具挑战性。在本研究中,我们分析了200例肝细胞癌(HCC)样本中一组20个融合基因,使用机器学习模型预测接受手术干预的HCC患者的复发率和生存率。结果显示,融合基因、Milan标准、血清甲胎蛋白(AFP)和病理分级对HCC复发具有中等预测准确性。然而,将选定的融合基因与这些临床参数相结合,显著提高了每个参数的预测准确性。当将融合基因模型应用于预测HCC患者3年生存率时,其表现优于Milan标准、病理分级和血清AFP。融合基因panel与Milan标准、病理分级或血清AFP的组合,相比这些临床参数单独使用产生了显著改善的结果。因此,检查HCC样本的融合基因状态可能有望成为评估该疾病临床结局的一种新的、改进的方法。
查看英文原文 English abstract
Hepatocellular carcinoma is one of the most lethal malignancies for humans. Assessing the clinical outcomes of HCC remains challenging. In this study, we analyzed a panel of 20 fusion genes in 200 hepatocellular carcinoma (HCC) samples to predict the recurrence and survival rates of HCC patients undergoing surgical interventions using machine learning models. The results showed that fusion genes, Milan criteria, serum alpha-fetal protein (AFP), and pathology grade had moderate predictive accuracy for HCC recurrence. However, the combination of selected fusion genes with these clinical parameters significantly enhanced the prediction accuracy of each parameter. When models of fusion genes were applied to predict the 3-year survival rate of HCC patients, they outperformed the Milan criteria, pathology grade, and serum AFP. The combination of a fusion gene panel with Milan criteria, pathology grade, or serum AFP yielded significantly improved results compared to those produced by these clinical parameters alone. As a result, examining the fusion gene status of HCC samples may hold promise as a new and improved approach to assessing the clinical outcomes of this disease.
利益披露 Disclosure
J. Luo,
MoleculeDx INC Other Business Ownership.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
none Other, none.
S. Liu, None.